Skip to main content
SpringerLink
Log in

Adjuvante Therapie mit Osimertinib bei operablem EGFR-mutiertem Lungenkarzinom

Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Taylor MD et al (2012) Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg 93(6):1813–1820 (discussion 1820-1)

    Article  Google Scholar 

  2. Sholl LM et al (2015) Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 10(5):768–777

    Article  CAS  Google Scholar 

  3. Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892–2911

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Herzchirurgie, herzchirurgische Intensivmedizin und Thoraxchirurgie, Universitätsklinikum Köln (AöR), Kerpener Str. 62, 50937, Köln, Deutschland

    Asmae Gassa

  2. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

    Filiz Özkan

  3. Klinik und Poliklinik für Allgemein‑, Viszeral- und Tumorchirurgie, Universitätsklinikum Köln (AöR), Köln, Deutschland

    Hakan Alakus &  Christiane Bruns

Authors
  1. Asmae Gassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filiz Özkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Alakus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christiane Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asmae Gassa.

Ethics declarations

Interessenkonflikt

A. Gassa, F. Özkan, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gassa, A., Özkan, F., Alakus, H. et al. Adjuvante Therapie mit Osimertinib bei operablem EGFR-mutiertem Lungenkarzinom. Onkologe 27, 172–173 (2021). https://doi.org/10.1007/s00761-020-00889-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-020-00889-1

Search

Navigation